Eli Lilly and Company (LLY)
Better Growth Play: Eli Lilly vs. Vanguard Growth Index Fund ETF Shares
Growth stocks have been in the spotlight since 1995. This year, Eli Lilly and the Vanguard Growth Index Fund ETF Shares have been top performers in the category.
3 Pharma Stocks That Could Make Your Grandchildren Rich
Pharmaceutical stocks have not set the world on fire, with a few exceptions. Since the pandemic ended, pharma stocks have largely fallen out of favor with investors amid declining sales and mixed financial results.
Eli Lilly (LLY) Beats Stock Market Upswing: What Investors Need to Know
In the most recent trading session, Eli Lilly (LLY) closed at $932.50, indicating a +1.58% shift from the previous trading day.
3 Moonshot Stocks With the Potential to Turn $10K Into $1 Million
With the Nasdaq and S&P 500 on a running spree, it is easy to pick stocks on momentum. But if you are investing for the long term, you need to pick stocks that will grow your money at little risk.
Novo Nordisk Falls as Study Says Eli Lilly Weight-Loss Ingredient More Effective
The stock price of a pair of pharmaceutical companies are moving in opposite directions Tuesday following the publication of a new scientific study, with Eli Lilly (LLY) shares rising and American depositary receipts (ADRs) of Danish drugmaker Novo Nordisk (NVO) slipping.
Why Lilly (LLY) is Poised to Beat Earnings Estimates Again
Lilly (LLY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Study Shows Lilly's (LLY) Obesity Drug More Effective Than NVO's
Data from a new study, also published on the JAMA website, shows that patients taking Lilly's (LLY) obesity drug are likely to lose more weight than those taking Novo's drug.
Eli Lilly (LLY) to Buy Morphic for $3.2B, Boost IBD Presence
Eli Lilly's (LLY) acquisition of Morphic (MORF) is set to expand its immunology pipeline by adding the latter's lead candidate, MORF-057, which is being developed for IBD conditions.
Novo Nordisk's stock slumps after study finds Wegovy lags Lilly's Mounjaro in speed and scale of weight loss
The stock of Danish biotech Novo Nordisk was down 1.6% premarket Tuesday, after a study found that the company's obesity drug Wegovy lags its main rival, Eli Lilly & Co. Inc.'s Mounjaro, in speed and magnitude of weight loss.
Is Eli Lilly Stock a No-Brainer Buy After Its FDA Alzheimer's Disease Drug Win?
Lilly's recently approved Alzheimer's disease drug Kisunla could generate peak annual sales of close to $5 billion. However, the drugmaker has even more important growth drivers than Kisunla.
Novo Nordisk shares down after analysis finds Lilly drug leads to better weight loss
Shares in Novo Nordisk , maker of the wildly popular obesity drug Wegovy were down 1.1% on Tuesday after the publication of a data analysis showing rival Eli Lilly's own treatment Mounjaro leads to faster and greater weight loss.
Eli Lilly Rose More Than 50% So Far This Year. Can It Soar Past $1,000 in the 2nd Half?
Eli Lilly stock has soared on optimism about its top-selling weight-loss drugs. The company is expanding infrastructure to meet demand -- and is studying new potential weight-loss drugs in late-stage trials.
